. 2015 Jul 20;33(24):2675–2682. doi: 10.1200/JCO.2015.61.0873

Table A1.

Median PFS and OS of Patients With Low-Grade Serous Carcinoma of Ovary or Peritoneum (N = 350)

Variable	No. of Patients	PFS^a			OS
Variable	No. of Patients	Months	95% CI	P	Months	95% CI	P
Age, years				< .001			< .001
≤ 35	88	18.8	14.2 to 23.5		79.7	58.2 to 101.3
> 35	262	32.6	26.8 to 38.5		111.3	91.4 to 131.2
Race				.11			.06
White	294	26.2	22.4 to 29.9		98.8	88.6 to 108.8
Nonwhite	56	41.6	23.4 to 59.8		129.0	72.2 to 185.8
Parity^b				.03			.28
Nulliparous	94	21.9	16.3 to 27.5		101.5	82.6 to 120.4
Parous	254	30.6	24.9 to 36.3		101.7	89.5 to 113.9
Smoking history^c				.36			.69
Never	216	25.3	21.3 to 29.3		100.6	89.5 to 111.8
Ever	133	32.2	25.5 to 38.8		107.0	72.8 to 141.2
BMI, kg/m^2d				.72			.98
Normal	82	31.6	21.7 to 41.5		107.0	74.6 to 139.5
Overweight	73	36.2	17.2 to 55.2		107.6	74.8 to 140.4
Obese	69	37.6	26.5 to 48.7		132.4	90.4 to 174.4
Pretreatment CA-125^e				.002			.40
< 35	35	44.1	0.00 to 91.0		134.4	66.0 to 202.7
> 35	187	23.5	20.7 to 26.3		95.2	84.7 to 105.6
FIGO stage^f				.02			.48
I to II	15	66.9	0.00 to 57.1		104.7	46.8 to 162.5
III to IV	321	25.9	21.5 to 27.9		101.5	90.7 to 112.3
Site				.02			.01
Ovary	275	25.4	21.4 to 29.3		95.2	84.8 to 105.5
Peritoneal	75	36.2	21.7 to 50.7		129.0	98.4 to 159.6
Surgery				.60			.93
None	5	30.5	0.00 to 78.1		132.4	35.9 to 228.9
Primary cytoreductive	317	26.4	22.4 to 30.4		101.5	90.5 to 112.4
Interval cytoreductive	28	34.6	11.9 to 57.3		106.5	74.5 to 138.5
Residual disease (primary CRS)^g				.44			.77
No gross residual	59	25.4	18.9 to 31.9		98.8	78.6 to 119.1
Gross residual	217	25.4	19.4 to 31.3		95.2	83.6 to 106.8
Chemotherapy^h				.70			.20
Adjuvant	305	26.4	22.2 to 30.5		100.8	89.9 to 111.7
Neoadjuvant	31	33.6	8.6 to 58.7		88.3	52.8 to 123.8
None	13	30.5	17.0 to 44.1		135.7	44.2 to 227.1
Maintenanceⁱ				.26			.03
None or missing information	202	30.0	24.3 to 35.8		113.9	91.7 to 136.1
Hormonal therapy	62	34.6	16.8 to 52.4		132.4	75.3 to 189.4
Chemotherapy	63	24.4	22.4 to 26.4		79.7	69.4 to 90.1
Chemotherapy plus hormonal therapy	14	19.7	0.0 to 44.8		86.5	76.3 to 96.7
Disease status at completion of primary treatment^j				< .001			< .001
NED	169	36.2	28.9 to 43.5		114.3	91.7 to 136.9
Disease present	126	18.7	12.7 to 24.7		80.9	67.3 to 94.4

Abbreviations: BMI, body mass index; CA-125, cancer antigen 125; CRS, cytoreductive surgery; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; NED, no evidence of disease; OS, overall survival; PFS, progression-free survival.

^{^a}

Twenty-seven patients were not included in PFS calculations because exact dates of recurrence were not documented in medical record, or there was interval of time for which no clinical data were available to document patient was diagnosed with recurrent disease.

^{^b}

Missing for two patients.

^{^c}

Not available for one patient.

^{^d}

Missing for 126 patients.

^{^e}

Missing for 128 patients.

^{^f}

Not available for 14 patients.

^{^g}

Missing for 74 patients.

^{^h}

Medical record of one patient who received chemotherapy did not include detailed information.

^ⁱ

Considered miscellaneous in nine patients; these patients were excluded.

^{^j}

Not available for 55 patients.